Company intelligence / Profile preview
FindCure Biosciences
Zhongshan, Guangdong Sheng, Chinago.gale.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
FindCure Biosciences is developing innovative targeted and immunotherapy drugs for cancer, with its lead small molecule AXL inhibitor, FC084CSA, in Phase 2 clinical trials for advanced malignant solid neoplasms. The company also focuses on digestive and respiratory disease areas but has not disclosed additional clinical-stage programs publicly.[1][2] No detailed clinical results are available in the public domain.
- Therapeutic areas
- GastroenterologyOncologyPulmonology
- Modalities
- Small molecule drugs
- Industry
- Biotech
02
Drug pipeline
9 assets8 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on FindCure Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FindCure Biosciences.